News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Deals
Amicus Therapeutics, Inc. Pulls $86M IPO Citing Market Conditions
August 4, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Amicus Therapeutics Inc. has withdrawn its initial public offering amid difficult market conditions, the latest in a spate of biopharmaceutical companies to do so.
>>>
Discuss This Story
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
Mergers & acquisitions
Lilly Validates Gene Editing Space With $1.3B Verve Buy, But Analysts Are Skeptical
June 17, 2025
·
3 min read
·
Annalee Armstrong
Mergers & acquisitions
A String of Biopharma Deals Has Piqued Analyst Interest in an M&A Return
June 17, 2025
·
3 min read
·
Annalee Armstrong
Collaboration
Partner-Seeking Biotechs Find Plenty of Hands To Shake as BIO2025 Kicks Off
June 16, 2025
·
2 min read
·
Jef Akst
Mergers & acquisitions
Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus
June 16, 2025
·
2 min read
·
Annalee Armstrong
